COLO.B.DK

690.8

-0.78%↓

GMAB.DK

1,250.5

-2.61%↓

ZEAL.DK

422.2

-8.69%↓

HLUNB.DK

30.24

-5.68%↓

AMBUB.DK

107.85

-1.51%↓

COLO.B.DK

690.8

-0.78%↓

GMAB.DK

1,250.5

-2.61%↓

ZEAL.DK

422.2

-8.69%↓

HLUNB.DK

30.24

-5.68%↓

AMBUB.DK

107.85

-1.51%↓

COLO.B.DK

690.8

-0.78%↓

GMAB.DK

1,250.5

-2.61%↓

ZEAL.DK

422.2

-8.69%↓

HLUNB.DK

30.24

-5.68%↓

AMBUB.DK

107.85

-1.51%↓

COLO.B.DK

690.8

-0.78%↓

GMAB.DK

1,250.5

-2.61%↓

ZEAL.DK

422.2

-8.69%↓

HLUNB.DK

30.24

-5.68%↓

AMBUB.DK

107.85

-1.51%↓

COLO.B.DK

690.8

-0.78%↓

GMAB.DK

1,250.5

-2.61%↓

ZEAL.DK

422.2

-8.69%↓

HLUNB.DK

30.24

-5.68%↓

AMBUB.DK

107.85

-1.51%↓

Search

Novo Nordisk A-S (Class B)

Chiusa

429.8 -5.94

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

428.25

Massimo

439.4

Metriche Chiave

By Trading Economics

Entrata

929M

28B

Vendite

14B

86B

P/E

Media del settore

20.778

63.778

EPS

6.34

Rendimento da dividendi

3.33

Margine di Profitto

32.947

Dipendenti

76,302

EBITDA

4.1B

39B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+9.53% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.33%

2.39%

Utili prossimi

7 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-31B

2.1T

Apertura precedente

435.74

Chiusura precedente

429.8

Novo Nordisk A-S (Class B) Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 apr 2025, 22:38 UTC

Azioni calde

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

25 feb 2025, 15:33 UTC

I principali Market Mover

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

5 feb 2025, 11:53 UTC

Utili

Novo Nordisk Outlook Provides Some Welcome Relief -- 2nd Update

5 feb 2025, 08:19 UTC

Utili

Novo Nordisk Expects Slowing Sales Growth This Year -- Update

2 apr 2025, 11:25 UTC

Discorsi di Mercato

Novo Nordisk Is a Screaming Buy, AlphaValue Says -- Market Talk

2 apr 2025, 09:27 UTC

Azioni calde

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

31 mar 2025, 12:49 UTC

Discorsi di Mercato

Novo Nordisk Had Constructive Quarter, But U.S. Volumes a Concern -- Market Talk

28 mar 2025, 15:11 UTC

Discorsi di Mercato

Novo Nordisk First Quarter Earnings Could Disappoint, BofA Says -- Market Talk

27 mar 2025, 13:45 UTC

Discorsi di Mercato
Utili

Novo Nordisk's Wegovy Sales Growth Stalls in U.S. Amid Competition, Reimbursement Hurdles -- Market Talk

24 mar 2025, 10:19 UTC

Discorsi di Mercato

Novo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk

24 mar 2025, 09:08 UTC

Discorsi di Mercato
Utili

Novo Nordisk Shares Could Remain Under Pressure for Now -- Market Talk

19 mar 2025, 15:54 UTC

Notizie principali

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

11 mar 2025, 15:31 UTC

Discorsi di Mercato

Novo Nordisk's CagriSema Trial Shows Disappointing Weight Loss -- Market Talk

11 mar 2025, 14:58 UTC

Discorsi di Mercato

Novo Nordisk's CagriSema Results Fail to Impress -- Market Talk

28 feb 2025, 12:00 UTC

Notizie principali

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

10 feb 2025, 12:00 UTC

Notizie principali

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7 feb 2025, 10:30 UTC

Notizie principali

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 feb 2025, 16:16 UTC

Notizie principali
Utili

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6 feb 2025, 14:56 UTC

Utili

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

5 feb 2025, 13:59 UTC

Utili

Novo Nordisk Outlook Provides Some Welcome Relief -- WSJ

5 feb 2025, 12:02 UTC

Utili

Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns. -- Barrons.com

5 feb 2025, 11:35 UTC

Discorsi di Mercato
Utili

Novo Nordisk's Earnings Report Should Get It Back On Track -- Market Talk

5 feb 2025, 10:10 UTC

Azioni calde

Stocks to Watch Wednesday: AMD, Alphabet, Novo Nordisk -- WSJ

5 feb 2025, 09:43 UTC

Utili

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

5 feb 2025, 08:47 UTC

Discorsi di Mercato
Utili

Novo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk

5 feb 2025, 08:38 UTC

Discorsi di Mercato
Utili

Novo Nordisk Earnings, Guidance Imply Consensus Upgrades -- Market Talk

5 feb 2025, 08:32 UTC

Utili

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

5 feb 2025, 08:30 UTC

Discorsi di Mercato
Utili

Novo Nordisk Sales Guidance Materially Ahead of Expectations -- Market Talk

5 feb 2025, 06:46 UTC

Utili

Novo Nordisk Expects to File For First Regulatory Approval of CagriSema During 1Q26

5 feb 2025, 06:45 UTC

Utili

Novo Nordisk Plans to Initiate New CagriSema Phase 3 Trial in 2025 to Further Explore Weight Loss Potential

Confronto tra pari

Modifica del prezzo

Novo Nordisk A-S (Class B) Previsione

Obiettivo di Prezzo

By TipRanks

9.53% in crescita

Previsioni per 12 mesi

Media 1,162.73 DKK  9.53%

Alto 1,550 DKK

Basso 720 DKK

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Novo Nordisk A-S (Class B) - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

7

Acquista

2

Mantieni

2

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.